AI Article Synopsis
- - Mesothelin (MSLN) is a cell-surface protein commonly targeted in antibody therapies, but its shedding into the bloodstream presents a challenge for these treatments.
- - The study has developed a monoclonal antibody that prevents MSLN from being shed, enhancing the effectiveness of CAR T cells.
- - By blocking the shedding of MSLN, the new antibody allows CAR T cells to remain active and shows potential for further research and development.
Article Abstract
SignificanceMesothelin (MSLN) is a cell-surface protein that is a popular target for antibody-based therapies. We have identified shed MSLN as a major obstacle to successful antibody therapies and prepared a monoclonal antibody that inhibits shedding and makes very active CAR T cells whose activity is not blocked by shed MSLN and merits further preclinical development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171807 | PMC |
| http://dx.doi.org/10.1073/pnas.2202439119 | DOI Listing |
Publication Analysis
Top Keywords
active car
8
car cells
8
highly active
4
cells bind
4
bind juxtamembrane
4
juxtamembrane region
4
region mesothelin
4
mesothelin blocked
4
blocked mesothelin
4
mesothelin significancemesothelin
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!